Sorrento's Share Price Woes Are In Remission, But The Long-Term Prognosis Is Far From CertainSeeking Alpha • 01/27/20
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain ConferencesGlobeNewsWire • 01/27/20
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in ChinaGlobeNewsWire • 01/06/20
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% PremiumThe Motley Fool • 12/05/19
Sorrento Therapeutics shares soar 25% after it rejects offer from two companiesMarket Watch • 11/25/19